|
Evaxion A/S
(NASDAQ: EVAX)
|
9:00 PM UTC, 12/12/25 | |||
|---|---|---|---|---|
| Last: $6.21 | Change: -0.24 | %Change: -3.72% | Volume: 70,895 | |
11:09 AM EDT, 03/13/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were treading water late Thursday morning, edging 0.1% higher to 1,396.7 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and pharmaceutical company Novo Nordisk (NVO), which rose 4.7% and 3.3% respectively. They were followed by pharmaceutical company Ascendis Pharma (ASND) and telecommunications operator Telefonica (TEF), which were up 1.7% and 1.5% respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and software firm SAP (SAP), which fell 2.7% and 2.3% respectively. They were followed by biotechnology companies argenx (ARGX) and Evaxion Biotech (EVAX), which dropped 2.1% and 0.9% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and telecommunications operator Vodafone Group (VOD), which increased 5.2% and 3% respectively. They were followed by pharmaceutical companies Amarin (AMRN) and AstraZeneca (AZN), which advanced 2.8% and 1.4% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and Barclays (BCS), which lost 2.7% and 2.4% respectively. They were followed by biopharmaceutical companies TC Biopharm (TCBP) and Silence Therapeutics (SLN), which were down 1.8% and 1.2% respectively.
http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.